• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

酸性β-葡萄糖苷酶:戈谢病的酶学与分子生物学

Acid beta-glucosidase: enzymology and molecular biology of Gaucher disease.

作者信息

Grabowski G A, Gatt S, Horowitz M

机构信息

Department of Pediatrics, Mount Sinai School of Medicine, New York, New York 10029.

出版信息

Crit Rev Biochem Mol Biol. 1990;25(6):385-414. doi: 10.3109/10409239009090616.

DOI:10.3109/10409239009090616
PMID:2127241
Abstract

Human lysosomal beta-glucosidase (D-glucosyl-acylsphingosine glucohydrolase, EC 3.2.1.45) is a membrane-associated enzyme that cleaves the beta-glucosidic linkage of glucosylceramide (glucocerebroside), its natural substrate, as well as synthetic beta-glucosides. Experiments with cultured cells suggest that in vivo this glycoprotein requires interaction with negatively charged lipids and a small acidic protein, SAP-2, for optimal glucosylceramide hydrolytic rates. In vitro, detergents (Triton X-100 or bile acids) or negatively charged ganglioside or phospholipids and one of several "activator proteins" increase hydrolytic rate of lipid and water-soluble substrates. Using such in vitro assay systems and active site-directed covalent inhibitors, kinetic and structural properties of the active site have been elucidated. The defective activity of this enzyme leads to the variants of Gaucher disease, the most prevalent lysosomal storage disease. The nonneuronopathic (type 1) and neuronopathic (types 2 and 3) variants of this inherited (autosomal recessive) disease but panethnic, but type 1 is most prevalent in the Ashkenazi Jewish population. Several missense mutations, identified in the structural gene for lysosomal beta-glucosidase from Gaucher disease patients, are presumably casual to the specifically altered posttranslational oligosaccharide processing or stability of the enzyme as well as the altered in vitro kinetic properties of the residual enzyme from patient tissues.

摘要

人溶酶体β-葡萄糖苷酶(D-葡萄糖基-酰基鞘氨醇葡萄糖水解酶,EC 3.2.1.45)是一种与膜相关的酶,可切割其天然底物葡萄糖神经酰胺(葡糖脑苷脂)以及合成β-葡萄糖苷的β-糖苷键。对培养细胞进行的实验表明,在体内,这种糖蛋白需要与带负电荷的脂质和一种小的酸性蛋白SAP-2相互作用,以实现最佳的葡萄糖神经酰胺水解速率。在体外,洗涤剂(Triton X-100或胆汁酸)或带负电荷的神经节苷脂或磷脂以及几种“激活蛋白”之一可提高脂质和水溶性底物的水解速率。使用此类体外测定系统和活性位点导向的共价抑制剂,已阐明了活性位点的动力学和结构特性。这种酶的活性缺陷会导致戈谢病的各种变体,戈谢病是最常见的溶酶体贮积病。这种遗传性(常染色体隐性)疾病的非神经病变型(1型)和神经病变型(2型和3型)在各民族中均有发生,但1型在德系犹太人群中最为常见。在戈谢病患者的溶酶体β-葡萄糖苷酶结构基因中鉴定出的几种错义突变,可能是导致翻译后寡糖加工或酶稳定性发生特异性改变以及患者组织中残留酶的体外动力学特性改变的原因。

相似文献

1
Acid beta-glucosidase: enzymology and molecular biology of Gaucher disease.酸性β-葡萄糖苷酶:戈谢病的酶学与分子生物学
Crit Rev Biochem Mol Biol. 1990;25(6):385-414. doi: 10.3109/10409239009090616.
2
Genetic heterogeneity in Gaucher disease: physicokinetic and immunologic studies of the residual enzyme in cultured fibroblasts from non-neuronopathic and neuronopathic patients.戈谢病的遗传异质性:非神经病变型和神经病变型患者培养成纤维细胞中残余酶的物理动力学和免疫学研究。
Am J Med Genet. 1985 Jul;21(3):529-49. doi: 10.1002/ajmg.1320210316.
3
Gaucher disease: accurate identification of asymptomatic French-Canadian carrier using nonlabeled authentic sphingolipid substrate N-palmitoyl dihydroglucocerebroside.戈谢病:使用未标记的天然鞘脂底物N-棕榈酰二氢葡萄糖脑苷脂准确鉴定无症状法裔加拿大携带者。
Am J Med Genet. 1987 Aug;27(4):895-905. doi: 10.1002/ajmg.1320270416.
4
Intracellular transport of acid beta-glucosidase and lysosome-associated membrane proteins is affected in Gaucher's disease (G202R mutation).在戈谢病(G202R突变)中,酸性β-葡萄糖苷酶和溶酶体相关膜蛋白的细胞内运输受到影响。
J Pathol. 1999 Aug;188(4):407-14. doi: 10.1002/(SICI)1096-9896(199908)188:4<407::AID-PATH377>3.0.CO;2-Z.
5
Non-neuronopathic Gaucher disease due to saposin C deficiency.由于鞘磷脂激活蛋白C缺乏导致的非神经元型戈谢病。
Clin Genet. 2007 Dec;72(6):538-42. doi: 10.1111/j.1399-0004.2007.00899.x. Epub 2007 Oct 7.
6
Mutations causing Gaucher disease.导致戈谢病的突变。
Hum Mutat. 1994;3(1):1-11. doi: 10.1002/humu.1380030102.
7
Acid beta-glucosidase: intrinsic fluorescence and conformational changes induced by phospholipids and saposin C.酸性β-葡萄糖苷酶:磷脂和鞘脂激活蛋白C诱导的内在荧光和构象变化
Biochemistry. 1998 Aug 18;37(33):11544-54. doi: 10.1021/bi980785+.
8
Gaucher disease: a membranous enzymopathy.戈谢病:一种膜性酶病。
Prog Clin Biol Res. 1982;97:193-215.
9
Use of activators and inhibitors to define the properties of the active site of normal and Gaucher disease lysosomal beta-glucosidase.使用激活剂和抑制剂来定义正常和戈谢病溶酶体β-葡萄糖苷酶活性位点的特性。
Enzyme. 1985;33(2):109-19. doi: 10.1159/000469416.
10
Miglustat (NB-DNJ) works as a chaperone for mutated acid beta-glucosidase in cells transfected with several Gaucher disease mutations.米格鲁司他(NB-DNJ)在转染了多种戈谢病突变的细胞中作为突变酸性β-葡萄糖苷酶的伴侣蛋白发挥作用。
Blood Cells Mol Dis. 2005 Sep-Oct;35(2):268-76. doi: 10.1016/j.bcmd.2005.05.007.

引用本文的文献

1
Bidirectional regulation of glycoprotein nonmetastatic melanoma protein B by β-glucocerebrosidase deficiency in isogenic dopaminergic neurons from a patient with Gaucher disease and parkinsonism.葡糖脑苷脂酶缺乏对戈谢病和帕金森病患者同基因多巴胺能神经元中糖蛋白非转移性黑色素瘤蛋白B的双向调节
bioRxiv. 2025 Jun 25:2025.06.23.661126. doi: 10.1101/2025.06.23.661126.
2
In Vitro Effects of Some Antibiotics on Purified β-Glucosidases from Rat Liver and Kidney Tissues.某些抗生素对大鼠肝脏和肾脏组织纯化β-葡萄糖苷酶的体外作用
Antibiotics (Basel). 2025 May 30;14(6):563. doi: 10.3390/antibiotics14060563.
3
Gaucher disease provides a unique window into Parkinson disease pathogenesis.
戈谢病为帕金森病发病机制的研究提供了一个独特的窗口。
Nat Rev Neurol. 2024 Sep;20(9):526-540. doi: 10.1038/s41582-024-00999-z. Epub 2024 Aug 6.
4
Recalibrating the Why and Whom of Animal Models in Parkinson Disease: A Clinician's Perspective.重新校准帕金森病动物模型的研究目的及适用对象:临床医生视角
Brain Sci. 2024 Jan 31;14(2):151. doi: 10.3390/brainsci14020151.
5
LRRK2 and Parkinson's disease: from genetics to targeted therapy.LRRK2 与帕金森病:从遗传学研究到靶向治疗。
Ann Clin Transl Neurol. 2023 Jun;10(6):850-864. doi: 10.1002/acn3.51776. Epub 2023 Apr 6.
6
Glucocerebrosidase mutations and Parkinson disease.葡萄糖脑苷脂酶突变与帕金森病。
J Neural Transm (Vienna). 2022 Sep;129(9):1105-1117. doi: 10.1007/s00702-022-02531-3. Epub 2022 Aug 6.
7
Variants and Parkinson Disease: Mechanisms and Treatments.变异与帕金森病:机制与治疗。
Cells. 2022 Apr 8;11(8):1261. doi: 10.3390/cells11081261.
8
Enzyme kinetics and inhibition parameters of human leukocyte glucosylceramidase.人白细胞葡萄糖神经酰胺酶的酶动力学和抑制参数
Heliyon. 2020 Nov 2;6(11):e05191. doi: 10.1016/j.heliyon.2020.e05191. eCollection 2020 Nov.
9
Synthesis of " Trihydroxypiperidines from a Carbohydrate-Derived Ketone: Hints for the Design of New β-Gal and GCase Inhibitors.从碳水化合物衍生的酮合成“三羟基哌啶:设计新的β-半乳糖苷酶和 GCase 抑制剂的提示。”
Molecules. 2020 Oct 2;25(19):4526. doi: 10.3390/molecules25194526.
10
Upregulating β-hexosaminidase activity in rodents prevents α-synuclein lipid associations and protects dopaminergic neurons from α-synuclein-mediated neurotoxicity.上调β-己糖胺酶活性可防止α-突触核蛋白与脂类结合,并保护多巴胺能神经元免受α-突触核蛋白介导的神经毒性。
Acta Neuropathol Commun. 2020 Aug 6;8(1):127. doi: 10.1186/s40478-020-01004-6.